Literature DB >> 32194754

Triple negative endometrial cancer: Incidence and prognosis in a monoinstitutional series of 220 patients.

Rosa Porzio1, Claudia Cordini2, Anna Maria Rodolfi2, Francesca Brigati2, Alessandro Ubiali3, Manuela Proietto1, Camilla Di Nunzio1, Luigi Cavanna1.   

Abstract

Endometrial cancer (EC) represents the most frequently occuring gynecological tumor worldwide. The aim of the present study was to estimate the prognostic value of triple negative phenotype (TNP) in EC, and any associations with to pathological and clinical characteristics. The present study includes 220 cases of patients with EC who underwent to surgery at the Guglielmo da Saliceto Hospital of Piacenza (Italy) and the expressions of estrogen receptor (ER), progesterone receptor (PR) and oncoprotein c-erbB-2 (HER2) expression were examined. Pearson's Chi-square and Fisher's exact test were used to evaluate the association of TNP cases with variables associated with a worse prognosis. Progression-free survival (PFS) and overall survival (OS) were analyzed with Kaplan-Meier curves. A total of 26 patients (12%) had a TNP, and these cases had a higher percentage of high-risk histology, an advanced stage of disease at the time of diagnosis, with shorter PFS and OS when compared to non-TNP. The present study confirmed that TNP represents prognostic significance in EC.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  endometrial cancer; gynecologic cancer; triple negative endometrial cancer

Year:  2020        PMID: 32194754      PMCID: PMC7039155          DOI: 10.3892/ol.2020.11329

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

1.  Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  N Colombo; E Preti; F Landoni; S Carinelli; A Colombo; C Marini; C Sessa
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

Review 2.  Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.

Authors:  S Kounelis; N Kapranos; E Kouri; D Coppola; H Papadaki; M W Jones
Journal:  Mod Pathol       Date:  2000-04       Impact factor: 7.842

3.  The prognostic significance of the triple negative phenotype in endometrial cancer.

Authors:  Rajul Kothari; Carl Morrison; Debra Richardson; Shelly Seward; David O'Malley; Larry Copeland; Jeffrey Fowler; David E Cohn
Journal:  Gynecol Oncol       Date:  2010-06-01       Impact factor: 5.482

Review 4.  Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.

Authors:  Carey K Anders; Lisa A Carey
Journal:  Clin Breast Cancer       Date:  2009-06       Impact factor: 3.225

5.  Molecular profiling of endometrial malignancies.

Authors:  Norasate Samarnthai; Kevin Hall; I-Tien Yeh
Journal:  Obstet Gynecol Int       Date:  2010-03-28

6.  Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.

Authors:  M A Khalifa; R S Mannel; S D Haraway; J Walker; K W Min
Journal:  Gynecol Oncol       Date:  1994-04       Impact factor: 5.482

7.  PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.

Authors:  Konstantin J Dedes; Daniel Wetterskog; Ana M Mendes-Pereira; Rachael Natrajan; Maryou B Lambros; Felipe C Geyer; Radost Vatcheva; Kay Savage; Alan Mackay; Christopher J Lord; Alan Ashworth; Jorge S Reis-Filho
Journal:  Sci Transl Med       Date:  2010-10-13       Impact factor: 17.956

8.  Clinical significance of CD151 overexpression in subtypes of invasive breast cancer.

Authors:  M J Kwon; S Park; J Y Choi; E Oh; Y J Kim; Y-H Park; E Y Cho; M J Kwon; S J Nam; Y-H Im; Y K Shin; Y-L Choi
Journal:  Br J Cancer       Date:  2012-01-31       Impact factor: 7.640

9.  A pathways-based prediction model for classifying breast cancer subtypes.

Authors:  Tong Wu; Yunfeng Wang; Ronghui Jiang; Xinliang Lu; Jiawei Tian
Journal:  Oncotarget       Date:  2017-06-17

10.  Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.

Authors:  Beate Jahn; Ursula Rochau; Christina Kurzthaler; Michael Hubalek; Rebecca Miksad; Gaby Sroczynski; Mike Paulden; Marvin Bundo; David Stenehjem; Diana Brixner; Murray Krahn; Uwe Siebert
Journal:  BMC Cancer       Date:  2017-10-16       Impact factor: 4.430

View more
  1 in total

1.  Elevated CA-125 Level and ER-Negative as Prognostic Factors for Ovarian Metastasis in Patients with Endometrial Cancer: A Retrospective Cohort Study.

Authors:  Xiaoting Ling; Zheyu Zheng; Jing Xu; Guocai Xu; Hui Zhou; Zhongqiu Lin; Yangyang Li; Jinxiao Liang; Huaiwu Lu
Journal:  Med Sci Monit       Date:  2020-12-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.